Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vibegron

            Therapeutic Area: Urology Product Name: Gemtesa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 23, 2021

            Details:

            Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxybutynin Chloride

            Therapeutic Area: Urology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2020

            Details:

            Strides Pharma Global has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the USFDA. Oxybutynin Chloride is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.

            BioSpecifics

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Collagenase Clostridium Histolyticum

            Therapeutic Area: Urology Product Name: Xiaflex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Endo Pharm

            Deal Size: $540.0 million Upfront Cash: $540.0 million

            Deal Type: Acquisition December 02, 2020

            Details:

            BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Desmopressin Acetate

            Therapeutic Area: Urology Product Name: Nocdurna

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: ANTARES PHARMA INC

            Deal Size: $25.0 million Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement October 01, 2020

            Details:

            This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tolterodine Tartrate

            Therapeutic Area: Urology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            Unichem Laboratories has received ANDA approval for its DETROL® (tolterodine tartrate) Tablets, USP 1 mg and 2 mg from the United States Food and Drug Administration (USFDA) to market a generic version of DETROL® (tolterodine tartrate) tablets of Pfizer Inc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Solifenacin

            Therapeutic Area: Urology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2020

            Details:

            VESIcare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population.